C.£1.5 million Contract Extension
IXICO plc has announced a contract extension worth approximately £1.5 million in additional revenue over the next three years, stemming from the continued progress of a Phase 2 clinical trial in Huntington's Disease with a major international pharmaceutical company. This extension, secured within two months of other new revenue totaling over £2.7 million from two existing clients, highlights the value of IXICO's AI-driven platform and neuroscience expertise in advancing drug development for neurological disorders.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
12 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the extension of an existing contract with one of the world's leading international pharmaceutical companies following the continued progress of a Phase 2 clinical trial in Huntington's Disease.
The contract extension is worth an additional c.£1.5 million in revenues to IXICO over the next three years.
Bram Goorden, CEO of IXICO, commented: "Thanks to this contract extension IXICO has secured over £2.7m in new revenues with 2 existing clients in the last 2 months. This is another example of how IXICO's compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.